Relevant bibliographies by topics / Platinum / Journal articles
To see the other types of publications on this topic, follow the link: Platinum.

Journal articles on the topic 'Platinum'

Author: Grafiati
Published: 4 June 2021
Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Platinum.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Tokura, Yuki, Shino Toma, Daisuke Takimoto, and Wataru Sugimoto. "Oxygen Reduction Reaction Activity of Platinum Nanosheets Derived from Layered Platinic Acid." ECS Meeting Abstracts MA2023-02, no. 40 (December 22, 2023): 1951. http://dx.doi.org/10.1149/ma2023-02401951mtgabs.

Full text
Abstract:
Platinum nanoparticles are mainly utilized as the cathode catalyst for polymer electrolyte fuel cells. However, the utilization of platinum for the oxygen reduction reaction (ORR) is insufficient and one must tackle the trade-off between high surface area and high stability. We have previously shown that metallic nanosheets such as ruthenium nanosheets exhibit high electrocatalytic activity and stability owing to the two-dimensional structure with an atomic scale thickness.1, 2 Platinum nanosheets, if available, should also have the potential to increase the utilization of the atoms and durability. While a few studies have reported the synthesis of platinum nanosheets,3 the thickness of the nanosheets is more than 1 nm, and the utilization of platinum has so far been lower than that of the Pt nanoparticles. In this study, we report double-layered platinum nanosheets derived from layered platinic acid.4 Layered platinic acid was synthesized through a solid-state-reaction and subsequent acid treatment. From the layered platinic acid, platinum oxide nanosheets were obtained as a colloid via chemical exfoliation. The thickness of the platinum oxide nanosheet was ~0.9 nm, consistent with the thickness of a single PtO6 octahedron. The platinum oxide nanosheets on silicon wafer were topotactically reduced to platinum nanosheets by mild thermal treatment in hydrogen. The thickness of the platinum nanosheet was ~0.5 nm, corresponding to a two atomic layer platinum nanosheet. Carbon supported platinum nanosheets were prepared by the reduction of platinum oxide nanosheets supported on carbon. The electrochemically active surface area (ECSA) of the carbon supported platinum nanosheets was 100 to 120 m2 (g-Pt)-1, which was considerably larger than that of 3 nm platinum nanoparticle (80 m2 (g-Pt)-1). In addition, the platinum nanosheet showed 1.7 times higher mass activity towards the oxygen reduction reaction compared to that of 3 nm platinum nanoparticles. Various methods for the topotactic reduction of platinum oxide nanosheets on carbon was studied. In addition to the mild thermal treatment in hydrogen gas, electrochemical reduction was also conducted. The ECSA of the platinum nanosheet prepared by electrochemical reduction at constant potential was 100 to 120 m2 (g-Pt)-1, which was almost same as the platinum nanosheet reduced by the mild thermal treatment in hydrogen. The specific activity was 1.2 to 1.3 times higher than that of the platinum nanosheet reduced by the mild thermal treatment in hydrogen. Therefore, the platinum nanosheet reduced by electrochemical reduction showed high mass activity for ORR. Acknowledgement This work was supported as part of the “Polymer Electrolyte Fuel Cell Program” and the FC-Platform projects from the New Energy and Industrial Technology Development Organization (NEDO) of Japan (20001201-0, 22101136-0). References [1] D. Takimoto, W. Sugimoto, Q. Yuan, N. Takao, T. Itoh, T. V. T. Duy, T. Ohwaki and H. Imai, ACS Appl. Nano Mater. 2, 5743 (2019). [2] W. Sugimoto and D. Takimoto, Chem. Lett. 50, 1304 (2021). [3] A. Funatsu, H. Tateishi, K. Hatakeyama, Y. Fukunaga, T. Taniguchi, M. Koinuma, H. Matsuura and Y. Matsumoto, Chem. Commun. 50, 8503 (2014). [4] D. Takimoto, S. Toma, Y. Suda, T. Shirokura, Y. Tokura, K. Fukuda, M. Matsumoto, H. Imai and W. Sugimoto, Nat. Commun. 14, 19 (2023).
APA, Harvard, Vancouver, ISO, and other styles
2

Wolford, Juliet Elizabeth, Jiaru Bai, Ramez Hassef Eskander, Robin Keller, Lindsey E. Minion, John K. Chan, Bradley J. Monk, and Krishnansu Sujata Tewari. "Evaluating the cost-effectiveness of current FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 5516. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5516.

Full text
Abstract:
5516 Background: Unlike approved IV administered therapies, Medicare is under no obligation to cover prescription medicines. We sought to evaluate the cost-effectiveness of the two FDA-approved orally administered PARP inhibitors (PARPi), olaparib and rucaparib. Methods: A Markov model was created in TreeAge Pro 2015 with nodes in the chain allowing patients to transition through response, hematological complications, non-hematological complications, progression, and death. Separately, the PARP inhibitors were compared with IV administered drugs approved for recurrent ovarian cancers including platinum-based, non-platinum, and bevacizumab-based regimens. Toxicity and mean PFS rates for the different agents were obtained from registration trial data. Costs of IV chemotherapy, managing toxicities, infusions, and supportive care were estimated using 2015 Medicare data. Incremental cost-effectiveness ratios (ICER) were calculated and survival was reported in quality adjusted life months. Results: Platinum-based combinations were the most cost-effective at $1,672/PFS mo as compared to non-platinum agents ($6,688/mo), bevacizumab-containing regimens ($12,482/mo), olaparib ($13,3731/mo), and rucaparib ($14,034/mo). Considering a cost of $114,478 for olaparib and $137,068 for rucaparib prior to progression, costs associated with PARPi were 7.1 to 8.3X more than platinum combinations. To better compare the registration trial data to PARPi data, probability was adjusted to 2nd line for rucaparib, revealing it’s ICERs’ of per month of life added to be $26,997 for bevacizumab, $17,757 for non-platinum, and $79,585 for platinums. Using the adjusted-to-2nd-line probabilities for olaparib, exhibited ICERs were $16,549 for bevacizumab, $25,637 for non-platinums and $72,083 for platinums. Conclusions: The high costs of PARPi were not balanced by costs of infusion and managing toxicities of IV drugs typically associated with lower response rates and shorter PFS in the recurrent space. Balancing incremental clinical benefit with novel therapies remains problematic and could widen disparities among those with limited access to care.
APA, Harvard, Vancouver, ISO, and other styles
3

Tofan, Lavinia, Carmen Păduraru, Laura Bulgariu, and Rodica Wenkert. "Perspectives on Analytical Methodology of Platinum Metals." Advanced Materials Research 95 (January 2010): 9–16. http://dx.doi.org/10.4028/www.scientific.net/amr.95.9.

Full text
Abstract:
In last years there is paid a special attention to the analytical chemistry of platinic metals (rhutenium, osmium, platinum, iridium, palladium, rhodium), due to increasing concerns on recovery and recirculation of these metals, especially platinum. In this context, recent data of specialty literature, regarding the approach of new methodological and chemical techniques in platinum metals determination from a variety of complex matrices and wide ranges of concentrations are systematized and briefly discussed.
APA, Harvard, Vancouver, ISO, and other styles
4

Shtemenko, A. V., and N. I. Shtemenko. "Rhenium–platinum antitumor systems." Ukrainian Biochemical Journal 89, no. 2 (April 24, 2017): 5–30. http://dx.doi.org/10.15407/ubj89.02.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bulgakov, Roman A., Nina A. Kuznetsova, Olga V. Dolotova, Ludmila I. Solovieva, John Mack, Wadzanai J. U. Chidawanyika, Oleg L. Kaliya, and Tebello Nyokong. "Synthesis and photophysical properties of covalent conjugates of aqua platinum(II) and octacarboxy-substituted zinc phthalocyanine." Journal of Porphyrins and Phthalocyanines 16, no. 11 (October 22, 2012): 1217–24. http://dx.doi.org/10.1142/s1088424612501209.

Full text
Abstract:
New covalent conjugates of aqua platinum(II) and octacarboxy-substituted zinc phthalocyanine, bearing one, two, three and four aqua platinum moieties on the periphery of the Pc ligand have been synthesized and characterized. The effect of the stepwise introduction of the aqua platinums on the photophysical and photochemical properties of these compounds has been investigated in dimethylsulfoxide solution. It has been found that aqua platinum moieties have only a limited effect on the dynamics of the singlet and triplet excited states, on the ability to sensitize singlet oxygen formation and on the photostability. Each conjugate has a high singlet oxygen quantum yield (ΦΔ 0.51–0.62) and thus retains potential for use as a dual action anticancer drugs by acting as a sensitizer for PDT in addition to the likely chemotherapeutic effects of the Pt(II) complexes.
APA, Harvard, Vancouver, ISO, and other styles
6

Wu, Baoyuan, and Ge Liu. "Platinum: Platinum-Rhodium Thermocouple Wire." Platinum Metals Review 41, no. 2 (April 1, 1997): 81–85. http://dx.doi.org/10.1595/003214097x4128185.

Full text
Abstract:
A new type of platinum:platinum-rhodium thermocouple wire which incorporates traces of yttrium in the platinum limb has been developed and tested in some typical working environments. This thermocouple possesses good thermal stability and mechanical strength at high temperatures, and a long service life, compared with conventional platinum:platinum-rhodium thermocouples. The thermocouple meets the output requirements of the Type S standard for thermocouples — those made of Pt:Pt-10%Rh — whose manufacturing tolerances are prescribed by the International Electrotechnical Commission (I.E.C.)(l). The life of thermocouples made from this wire is increased by around 1.5 to 2 times and they display a greater resistance to contamination.
APA, Harvard, Vancouver, ISO, and other styles
7

Muenchen, H. J., S. K. Aggarwal, H. K. Misra, and P. J. Andrulis. "Morphological and Histochemical Changes in Macrophage Activity After Novel Anti-Neoplastic Platinum Agents." Microscopy and Microanalysis 3, S2 (August 1997): 11–12. http://dx.doi.org/10.1017/s1431927600006942.

Full text
Abstract:
Poly-[(trans-1,2-diaminocyclohexane) platinumj-carboxyamylose (“poly-plat”), 5-sulfosalicylato-trans -(1,2-diaminocyclohexane) platinum (SSP), and 4-hydroxy-∝-sulfonylphenylacetato (trans 1,2-diaminocyclohexane) platinum (II) (SAP) are second generation analogs of cisplatin (CDDP) with higher efficacy and potency than cisplatin. This is particularly true of “poly-plat” which contains 1/5 the platinum of CDDP. In order to understand the mechanism of action of these compounds, isolated murine peritoneal macrophages in culture medium were treated with “poly-plat”, SSP, or SAP (5 μg/ml) for 2 h. Drug containing medium was then replaced with fresh medium and the cells were allowed to incubate at 37° C (5% CO2) for 24 h. Supernatants were collected at 0.5, 1, 2, and 24 h post-treatment for immunocytochemical analysis. Confocal microscopy studies demonstrated an increase in the number of lysosomes in the treated macrophages, but only “poly-plat” and SSP treated macrophages were stimulated to form cytoplasmic extensions at 2 h and 24 h.
APA, Harvard, Vancouver, ISO, and other styles
8

YARITA, Somei. "Platinum, Platinum Alloy Plating and Platinum Group Metals Electroforming Technology." Journal of the Surface Finishing Society of Japan 55, no. 10 (2004): 646. http://dx.doi.org/10.4139/sfj.55.646.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pishvaian, Michael J., Edik Matthew Blais, Jonathan Robert Brody, Davendra Sohal, Andrew Eugene Hendifar, Vincent Chung, Sameh Mikhail, et al. "Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program." Journal of Clinical Oncology 37, no. 4_suppl (February 1, 2019): 191. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.191.

Full text
Abstract:
191 Background: Up to 17% of PDAs harbor mutations in the DDR pathway. However, the purely prognostic relevance of these mutations is unclear. Furthermore, outcomes in response to platinum-based therapies in PDA pts harboring mutations in a broad range of DDR genes, particularly beyond BRCA1/2 and PALB2, remain unexplored. Methods: We evaluated PDA pts enrolled in the KYT registry for whom we collected cancer related exome sequencing and clinical outcomes. Pts were categorized as resected and advanced (LAPC and metastatic pts), and tumor genomic profiles were categorized as DDR mutated (DDRmut) based on the presence of pathogenic alterations in BRCA1/2, PALB2 (Group 1), ATM, ATR, ATRX (Group 2), or BAP1, BARD1, BRIP1, CHEK1/2, RAD50/51/51B, or FANCA/C/D2/E/F/G/L (Group 3). Tumors harboring no DDR mutations were labelled DDR proficient (pDDR). Median overall survival (OS) was measured from the date of diagnosis until death. Results: The OS was similar in all resected pts, irrespective of exposure to platinum therapy (see Table). However, for the pts with advanced disease, OS was significantly longer for DDRmut vs. pDDR pts, particularly in the platinum-treated group; but no such difference was identified in the platinum-naïve pts. Detailed outcomes for the 3 Groups will be presented, but in general the OS in pts with mutations in all 3 DDRmut Groups was greater than for the pDDR pts; but again this difference was lost in the platinum-naïve pts. Conclusions: Advanced DDRmut pts have an improved OS when treated with platinums, compared to pDDR pts. But, in the absence of platinum-based therapy, there is no OS difference observed in DDRmut vs. pDDR pts, suggesting that DDR status has no pure prognostic value. These findings support the need to test all pts with advanced PDA, to ensure that DDRmut pts are treated with platinum-based therapy. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
10

Martelli, O., M. Cinquini, A. Mancuso, K. Borgonovo, F. Petrelli, C. Sergi, D. Paleari, S. Fatigoni, A. Sdrobolini, and S. Aglione. "The efficacy of second line chemotherapy (CHT) in platinum-sensitive advanced/metastatic small cell lung cancer (SCLC) patients: Results of an ongoing Italian multicenter survey." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 18090. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.18090.

Full text
Abstract:
18090 Background: Despite CHT and radiotherapy for SCLC, most patients (pts) die within 2 years. Response rates for second-line CHT are low, with a median survival of 5 months in platinum-refractory pts. Re-challenge with platinum salts or salvage regimens is a standard option for pts with platinum-sensitive disease with a median overall survival (OS) of 6.5–8 months (Chua et al., Cancer Treat Rev. 2004). The purpose of this study was to explore the benefits of different second line regimens in this platiunum sensitive population. Methods: Clinical records of 73 platinum sensitive SCLC pts (first line relapse free survival > 6 months) were reviewed from 13 medical oncology departments in Italy from January 1993 to December 2006. Pt. characteristics: 59 males, 14 females, median age 64 years (range 27–93), median ECOG performance status (PS): 1, limited/extended disease: 33/40 pts. Pts received salvage chemotherapy which consisted of monotherapy in 37% and platinum-containing doublets in 55%. Doublets without platinum salts were administered in the remaining 8%. Results: Of 67 evaluable pt, second line CHT produced partial responses (PR) in 58 (79%) and stable disease (SD) in 9 pts (12%) by RECIST criteria. Overall tumor growth control (PR+SD) was 91%. Despite these encouraging results, the median TTP was 3 months and OS for all evaluable pts was 6.5 months. Survival at 1 year was 11%. Multivariate analysis revealed that the most important prognostic factor for response was age ( p<0.04) and there was no statistically significant difference between platinum-based regimens and monotherapy. Multivariate analysis showed no impact on survival by prior response to first line treatment, female sex or smoking status. Conclusions: Within the limits of a retrospective study, despite the high rate of responses obtainable in this setting, TTP and OS do not appear significantly improved by salvage regimens. Second line CHT has marginal activity and should be considered only in younger pts with a good PS. On the basis of these results, re-treatment with platinum salts could be avoided in these pts. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
11

Soriano, C. M. "Platinum." IEEE Potentials 16, no. 5 (1998): 29–32. http://dx.doi.org/10.1109/45.645836.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Wolter, H. "Platinum." Allgemeine Homöopathische Zeitung 232, no. 02 (April 10, 2007): 45–51. http://dx.doi.org/10.1055/s-2006-936181.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Wolter, H. "Platinum." British Homoeopathic journal 76, no. 3 (July 1987): 160–61. http://dx.doi.org/10.1016/s0007-0785(87)80072-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

GROSS, RICHARD M. "PLATINUM." Chemical & Engineering News 81, no. 36 (September 8, 2003): 149. http://dx.doi.org/10.1021/cen-v081n036.p149.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Young, Jay A. "Platinum." Journal of Chemical Education 86, no. 2 (February 2009): 163. http://dx.doi.org/10.1021/ed086p163.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Hausen, D. M. "Platinum." JOM 40, no. 4 (April 1988): 60. http://dx.doi.org/10.1007/bf03259025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Tsukada, Keiji, Yuji Miyahara, and Hiroyuki Miyagi. "Platinum-Platinum Oxide Gate pH ISFET." Japanese Journal of Applied Physics 28, Part 1, No. 12 (December 20, 1989): 2450–53. http://dx.doi.org/10.1143/jjap.28.2450.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Stang, Peter J., and Jeffery A. Whiteford. "Mixed, Neutral-Charged, Platinum-Platinum and Platinum-Palladium Macrocyclic Tetranuclear Complexes." Organometallics 13, no. 10 (October 1994): 3776–77. http://dx.doi.org/10.1021/om00022a010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Blau, Reed J., and James H. Espenson. "Correlations of platinum-195-phosphorus-31 coupling constants with platinum-ligand and platinum-platinum bond lengths in platinum(I) dimers and in related platinum(II) complexes." Inorganic Chemistry 25, no. 6 (March 1986): 878–80. http://dx.doi.org/10.1021/ic00226a033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Multhaupt, T. P., and S. K. Aggarwal. "Novel Second Generation Platinum Containing Antineoplastic Agents Ssp, Sap, and Poly-Plat and Their Effect on Glucose 6 Phosphate Dehydrogenase (Ec 1.1.1.49) in the Liver and Kidney of Male Wistar Rats." Microscopy and Microanalysis 3, S2 (August 1997): 57–58. http://dx.doi.org/10.1017/s1431927600007170.

Full text
Abstract:
Poly-(trans-l,2-diaminocyclohexane) platinumj-carboxyamylose (Poly-Plat); 5-SuIfosalicylato-trans-(l,2-diaminocyclohexane) platinum (SSP); and 4-Hydroxy-a-sulfonylphenylacetato (trans 1,2-diaminocyclohexane) platinum (II) (SAP) (Andrulis Pharmaceuticals, Bethesda, MD) are three novel second generation platinum containing antineoplastic compounds. Initial studies indicate that these agents are more effective in the treatment of cancer while at the same time less toxic to the organism as a whole than cisplatin (CDDP). The present study was undertaken to examine the effects of these new compounds on glucose-6-phosphate dehydrogenase (G-6-PDH) as compared to CDDP treated and normal kidney and liver tissues.Wistar rats (100-120g) were given intraperitoneal injections of CDDP (9 mg/ kg) and Poly-Plat, SSP and SAP (10 mg/ kg) over a 5 day period. On day 6 the animals were sacrificed and tissues (kidney and liver) were freeze sectioned (7 μm). Sections were incubated in media according to the accepted method specific for the G-6-PDH localization at a pH of 7.46 for 30 min.
APA, Harvard, Vancouver, ISO, and other styles
21

Chotkowski, Maciej, Franciszek Miklaszewicz, and Andrzej Czerwinski. "The Platinum Catalyst Prepared from Platinum Carbonyls." Journal of New Materials for Electrochemical Systems 16, no. 4 (October 4, 2013): 263–67. http://dx.doi.org/10.14447/jnmes.v16i4.151.

Full text
Abstract:
Pt catalysts for methanol electro-oxidation were prepared by thermal decomposition of platinum carbonyls. [Pt3(CO)6]n2- were synthesized from inorganic platinum compounds (PtCl4 or (NH4)2PtCl4) in H2O-MeOH solutions using carbon monoxide as a reducing agent. The progress of the platinum carbonyls synthesis reaction and its performance were monitored using UV-Vis spectroscopy. The obtained results clearly indicate the possibility of using platinum carbonyls as intermediates for the synthesis of pure and finely divided platinum particles. The electrochemical tests of the platinum powders performed in the polymer-electrolyte low-temperature methanol fuel cells (DMFC) indicated good electrocatalytic properties of these materials.
APA, Harvard, Vancouver, ISO, and other styles
22

Afria, Rengki, Julisah Izar, Neldi Harianto, Mar'atun Sholiha, and Wahyu Adelia. "Analisis Afiksasi Pada Lagu Rossa dalam Album Platinum Collection." Kajian Linguistik dan Sastra 2, no. 2 (May 15, 2023): 186–94. http://dx.doi.org/10.22437/kalistra.v2i2.24931.

Full text
Abstract:
Penelitian ini bertujuan untuk mendeskripsikan penggunaan afiksasi di dalam lagi Rossa pada album Platinum Collection. Penelitian ini menggunakan metode deskriptif kualitatif. Data yang digunakan berasal dari lirik lagu Rossa pada album Platinum Collection yang terdapat pada situs internet. Teori yang digunakan yaitu afiksasi, afiks, dan bentuk afiks. Masalah yang dibahas yaitu penggunaan afiks pada lagu Rossa dalam album Platinum Collection. Dari hasil penelitian ditunjukkan bahwa banyak penggunaan afiksasi di dalam lagu Rossa. Terdapat 122 kata yang mengandung afiksasi dalam lirik lagu Rossa album Platinum Collection. Dari 122 data kata berafiks yang ditemukan, prefiks memilki peesentase penggunaan paling tinggi. Yaitu sebanyak 58 data yang terdiri atas prefiks me-, ber-, se-, ter- dan, meN-. Prefiks yang paling banyak ditemukan adalah prefiks ber-, sedangkan prefiks yang paling sedikit ditemukan adalah prefiks se-. Sufiks yang ditemukan sebanyak 53 data yang terdiri atas -kan, -nya, -i, -lah, dan -kah. Sufiks yang paling banyak ditemukan adalah sufiks -kan, sedangkan sufiks yang paling sedikit ditemukan adalah sufiks -lah. Konfiks yang ditemukan sebanyak 11 data yang terdiri atas konfiks ke-an, pe-an dan se-nya. Abstract The purpose of this study is to describe the use of affixation in the album Platinum Collection song Rossa. This research was conducted by using qualitative descriptive method. The data are taken from the album Platinum Collection by Rossa in the internet site. The theory are used affixes, prefix, sufix and confix. Based on the research there is a lot of use of affixation in lyrics songs Rossa on the Platinum collection album. The result of research on the affixation analysis in the album Platinun Collection song Rossa from 3 kinds of affixation it can be concluded that. There are 122 prefixes. The prefix found in 58 data consists of prefix me-, ber-, se-, ter- and meN-. The most common prefix is ber-, whereas the prefix is the smallest is prefix se-. The surffix found in 53 data, consisting of surffix -kan, -nya, -i, -lah, and -kah. The most commonly found suffix is the suffix -kan, whereas the suffix with the least frequency of occurrences is the suffix -lah. The confix found in 11 data, consists of words that have confix ke-an, pe-an and se-nya.
APA, Harvard, Vancouver, ISO, and other styles
23

Newman, Christopher P., Gareth W. V. Cave, Michael Wong, William Errington, Nathaniel W. Alcock, and Jonathan P. Rourke. "Di-metallated platinum carbonyl complexes: platinum–platinum interactions in the solid state." Journal of the Chemical Society, Dalton Transactions, no. 18 (2001): 2678–82. http://dx.doi.org/10.1039/b105073g.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Yumuk, P. F., M. Teomete, F. Dane, D. Cabuk, G. Basaran, and N. S. Turhal. "Impact of dose reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e19055-e19055. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e19055.

Full text
Abstract:
e19055 Background: Platinum compounds are the main component of the CT in NSCLC. Standard recommended doses of cisplatin/carboplatin is usually couldn’t be administered and dose reductions are necessary because of side effects. We aimed to determine the effect of dose reductions of platinums on outcome of stage IIIB/IV NSCLC. Methods: Data of 420 patients were retrospectively reviewed. A platinum analogue was used in combination with vinorelbine, gemcitabine, paclitaxel, docetaxel or etoposide as first line treatment in 85% patients. Cumulative platinum doses and dose reduction ratios compared to standard doses were calculated. Patients with decreased GFR were excluded from the analysis. Results: Median age was 60 years (range: 28-87), 79% of patients were male, 31% were 65 yearsold/older, 55% had PS of 0, and 27% had stage IIIB disease. Histological subtypes were squamous cell in 32%, adenocarcinoma in 34%, and NSCLC in 31%. Median dose of cisplatin used per cycle was 67mg/m2 and carboplatin was 287mg/m2. 51% of the patients received standard or less than 10% reducted doses of platinum, while dose reductions were 10–20% in 19%, 21–30% in 24% of patients, and more than 31% in 6%. Median overall survival (OS) was 11 months, 1- year and 2-year OS ratios were 56% and 25%, respectively. Median time to progression was 5 months; 1-year progression free survival ratio was 18%. Gender, age, histologic subtype, and treatment with lower dose of platinum didn’t have any statistically significant impact on survival in univariate analysis. Patients with PS of 0, no weight loss, stage IIIB disease, receiving combination CT with docetaxel-cisplatin, and having partial response to treatment lived significantly longer. On multivariate analysis weight loss, stage and type of response to treatment had an impact on OS. Conclusions: Using lower doses of platinum compounds in combination chemotherapy for stage IIIB/IV non-small cell lung cancer might not have a negative impact on survival and definitely have a better toxicity profile. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
25

Wawrzyńczak, Agata, Hieronim Maciejewski, and Ryszard Fiedorow. "Hydrosilylation on Hydrophobic Material Supported Platinum Catalysts." Vestnik Volgogradskogo gosudarstvennogo universiteta. Serija 10. Innovatcionnaia deiatel’nost’, no. 1 (March 2015): 42–52. http://dx.doi.org/10.15688/jvolsu10.2015.1.6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Feldmann, Daniel P., Joshua Heyza, Christoph M. Zimmermann, Steve M. Patrick, and Olivia M. Merkel. "Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy." Molecules 25, no. 8 (April 24, 2020): 1994. http://dx.doi.org/10.3390/molecules25081994.

Full text
Abstract:
Platinum-based chemotherapy remains a mainstay treatment for the management of advanced non-small cell lung cancer. A key cellular factor that contributes to sensitivity to platinums is the 5′-3′ structure-specific endonuclease excision repair cross-complementation group 1 (ERCC1)/ xeroderma pigmentosum group F (XPF). ERCC1/XPF is critical for the repair of platinum-induced DNA damage and has been the subject of intense research efforts to identify small molecule inhibitors of its nuclease activity for the purpose of enhancing patient response to platinum-based chemotherapy. As an alternative to small molecule inhibitors, small interfering RNA (siRNA) has often been described to be more efficient in interrupting protein–protein interactions. The goal of this study was therefore to determine whether biocompatible nanoparticles consisting of an amphiphilic triblock copolymer (polyethylenimine-polycaprolactone-polyethylene glycol (PEI-PCL-PEG)) and carrying siRNA targeted to ERCC1 and XPF made by microfluidic assembly are capable of efficient gene silencing and able to sensitize lung cancer cells to cisplatin. First, we show that our PEI-PCL-PEG micelleplexes carrying ERCC1 and XPF siRNA efficiently knocked down ERCC1/XPF protein expression to the same extent as the standard siRNA transfection reagent, Lipofectamine. Second, we show that our siRNA-carrying nanoparticles enhanced platinum sensitivity in a p53 wildtype model of non-small cell lung cancer in vitro. Our results suggest that nanoparticle-mediated targeting of ERCC1/XPF is feasible and could represent a novel therapeutic strategy for targeting ERCC1/XPF in vivo.
APA, Harvard, Vancouver, ISO, and other styles
27

Baumgärtner, M. E., and J. Raub. "The Electrodeposition of Platinum and Platinum Alloys." Platinum Metals Review 32, no. 4 (October 1, 1988): 188–97. http://dx.doi.org/10.1595/003214088x324188197.

Full text
Abstract:
Work on the electrolytic deposition of platinum and some platinum alloys is reviewed, and the results of our recent work on the deposition and the properties of the layers produced from some promising electrolytes are briefly discussed. In general, studies of plating solutions are restricted by the economic availability of the relevant platinum salts. On the other hand the hydrolysis of the platinum salts in solution, and the incorporation of decomposition products are also critical factors, especially for their influence on internal stress. Recent work has shown that it is possible to deposit platinum-cobalt alloys which have excellent magnetic and mechanical properties, and these alloy deposits look very promising for data storage applications and for small permanent magnet layers.
APA, Harvard, Vancouver, ISO, and other styles
28

Anderson, Bernard M., and Stephanie K. Hurst. "Platinum Stacking Interactions in Homoleptic Platinum Polymers." European Journal of Inorganic Chemistry 2009, no. 21 (July 2009): 3041–54. http://dx.doi.org/10.1002/ejic.200900225.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Dimakis, Nicholas, Fernando A. Flor, Nestor E. Navarro, Andres Salgado, and Eugene S. Smotkin. "Adsorption of Carbon Monoxide on Platinum–Ruthenium, Platinum–Osmium, Platinum–Ruthenium–Osmium, and Platinum–Ruthenium–Osmium–Iridium Alloys." Journal of Physical Chemistry C 120, no. 19 (May 6, 2016): 10427–41. http://dx.doi.org/10.1021/acs.jpcc.6b02086.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Zhang, Ruiquan, Zhou Zhang, Qing Chen, Maocong Hu, and Zhenhua Yao. "Revolutionizing Fuel Cell Efficiency with Non-Metallic Catalysts for Oxygen Reduction Reactions." Global Environmental Engineers 9 (December 25, 2022): 49–59. http://dx.doi.org/10.15377/2410-3624.2022.09.4.

Full text
Abstract:
Platinum-based catalysts are widely used in oxygen reduction reactions, but platinum’s high cost and low reserves have restricted their sustainable development. With continuous in-depth research, it has been found that metal-free catalysts also have better catalytic activity in oxygen reduction reactions and have great potential for development due to the low cost and abundant reserves of metal-free catalysts, which has become a hot research direction. This paper reviews the application of metal-free catalysts in oxygen reduction reactions, including heteroatom-doped carbon-based catalysts, polymeric nitrogen catalysts, and emerging carbon catalysts. This work provides insights into developing non-platinum catalysts for oxygen reduction reactions by comparing the catalytic activity, selectivity, and prolonged stability.
APA, Harvard, Vancouver, ISO, and other styles
31

Rose, P. G. "Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma." International Journal of Gynecologic Cancer 15, Suppl 1 (2005): 18–22. http://dx.doi.org/10.1136/ijgc-00009577-200505001-00004.

Full text
Abstract:
Platinum compounds are the key components of chemotherapy for ovarian cancer. Preclinical models in an ovarian cancer cell line (A2780) have demonstrated synergistic activity when gemcitabine is added to cisplatin compared with either single agent alone. Furthermore, the combination leads to increased platinum-adduct retention as a result of decreased DNA repair compared with cisplatin alone. Inhibition of specific exonucleases, such as excision repair cross-complementation group 1 (ERCC1), is integral to the platinum–gemcitabine synergy. In platinum-sensitive recurrent ovarian cancer patients (defined as those patients whose cancer recurs after >6 months following primary therapy), platinum and gemcitabine have demonstrated an improvement in progression-free survival compared with platinum alone. This is also true for the patients who are only moderately platinum sensitive (defined as those patients who have cancer recurring 6–12 months after primary therapy). Increasing numbers of phase II experiences have demonstrated the activity of the platinum–gemcitabine combination in patients defined as platinum resistant (those with disease progression on therapy or whose disease recurs within 6 months of a platinum-based regimen).
APA, Harvard, Vancouver, ISO, and other styles
32

Khokhlova, S. V., M. V. Cherkasova, N. F. Orel, S. V. Limareva, I. Ya Bazaeva, and V. A. Gorbunova. "WHICH PATIENTS WITH OVARIAN CANCER SHOWS THE COMBINATION OF TRABECTEDIN WITH PEGYLATED LIPOSOMAL DOXORUBICIN." Annals of the Russian academy of medical sciences 68, no. 11 (November 12, 2013): 115–21. http://dx.doi.org/10.15690/vramn.v68i11.852.

Full text
Abstract:
Given the high rate of recurrence of ovarian cancer, the search for new therapeutic strategies are topical issue. According to various studies the effectiveness of drug treatment relapse depends on the platinum-free interval, increasing in proportion to its duration. If therapy is platinum-resistant recurrent ovarian cancer is a standard approach, the treatment of platinum-sensitive recurrent algorithm is not fully defined. Comparison of platinum and non-platinum combinations revealed the advantage of combined platinum- treatment for patients with platinum-free interval of more than 6 months without an increase in life expectancy. Non-platinum combination of trabectedin with pegylated liposomal doxorubicin has shown comparable efficacy with an advantage in overall survival in patients with platinum-free interval of 6–12 months. A platinum-free interval prolongation by the use of non-platinum mode increases the efficiency of subsequent platinum-based therapy, increasing the life expectancy of patients . Currently under study molecular markers and prognostic factors allowing to define a group of patients who have the greatest benefit from the use trabectedin with pegylated liposomal doxorubicin as second-line chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
33

Pollack, Howard, Joan Tower, Carman Moore, David Chaitkin, John Melby, and James Tenney. "Platinum Spirals." American Music 5, no. 4 (1987): 469. http://dx.doi.org/10.2307/3051465.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Alemayehu, Abraham B., Hugo Vazquez-Lima, Christine M. Beavers, Kevin J. Gagnon, Jesper Bendix, and Abhik Ghosh. "Platinum corroles." Chem. Commun. 50, no. 76 (June 9, 2014): 11093–96. http://dx.doi.org/10.1039/c4cc02548b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

&NA;. "Platinum complexes." Reactions Weekly &NA;, no. 508 (July 1994): 12. http://dx.doi.org/10.2165/00128415-199405080-00062.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Hennessy, James. "Pinpointing platinum." Nature Materials 14, no. 11 (October 22, 2015): 1075. http://dx.doi.org/10.1038/nmat4471.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Song, Yujiang, Ying-Bing Jiang, Haorong Wang, Donovan A. Pena, Yan Qiu, James E. Miller, and John A. Shelnutt. "Platinum nanodendrites." Nanotechnology 17, no. 5 (February 7, 2006): 1300–1308. http://dx.doi.org/10.1088/0957-4484/17/5/023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Prichard, H. M. "International Platinum." Mineralogical Magazine 63, no. 5 (1999): 773. http://dx.doi.org/10.1180/minmag.1999.063.5.16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Lavine, M. S. "Stacked Platinum." Science 329, no. 5987 (July 1, 2010): 15. http://dx.doi.org/10.1126/science.329.5987.15-b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Abramov, P. A., C. Vicent, N. B. Kompankov, A. L. Gushchin, and M. N. Sokolov. "Platinum polyoxoniobates." Chemical Communications 51, no. 19 (2015): 4021–23. http://dx.doi.org/10.1039/c5cc00315f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Marsh, Sharon, Howard McLeod, Eileen Dolan, Sunita J. Shukla, Cara A. Rabik, Li Gong, Tina Hernandez-Boussard, Xing Jian Lou, Teri E. Klein, and Russ B. Altman. "Platinum pathway." Pharmacogenetics and Genomics 19, no. 7 (July 2009): 563–64. http://dx.doi.org/10.1097/fpc.0b013e32832e0ed7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Ollendorff, R. L., G. Bosˇković, and J. B. Butt. "Platinum/alumina." Applied Catalysis 62, no. 1 (June 1990): 85–103. http://dx.doi.org/10.1016/s0166-9834(00)82239-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

RITTER, STEVE. "PLATINUM MOLES." Chemical & Engineering News Archive 82, no. 10 (March 8, 2004): 9. http://dx.doi.org/10.1021/cen-v082n010.p009a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Morrissey, Ronald J. "Platinum plating." Metal Finishing 98, no. 1 (January 2000): 291. http://dx.doi.org/10.1016/s0026-0576(00)80336-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Morrissey, Ronald J. "Platinum plating." Metal Finishing 97, no. 1 (January 1999): 292–96. http://dx.doi.org/10.1016/s0026-0576(00)83087-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

TULLO, ALEXANDER H. "GOING PLATINUM." Chemical & Engineering News 80, no. 34 (August 26, 2002): 17–19. http://dx.doi.org/10.1021/cen-v080n034.p017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Morrissey, Ronald J. "Platinum plating." Metal Finishing 99 (January 2001): 291. http://dx.doi.org/10.1016/s0026-0576(01)85287-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Morrissey, Ronald J. "Platinum plating." Metal Finishing 100 (January 2002): 277. http://dx.doi.org/10.1016/s0026-0576(02)82029-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Morrissey, Ronald J. "Platinum plating." Metal Finishing 97, no. 1 (January 1999): 296. http://dx.doi.org/10.1016/s0026-0576(99)80029-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Ball, Philip. "Platinum sales." Nature Materials 5, no. 7 (July 2006): 520. http://dx.doi.org/10.1038/nmat1684.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Platinum' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography